Verdiva Bio is advancing a portfolio of next‑generation oral and injectable treatments targeting obesity and related cardiometabolic conditions, including oral and subcutaneous amylin and GLP‑1 programs. Its lead asset, VRB‑101, is an oral GLP‑1 peptide that showed best‑in‑class efficacy potential and once‑weekly dosing viability in a Phase 1 study in Australia. The company emphasizes a clinically validated proprietary oral delivery technology intended to enable patient‑friendly dosing, greater scalability, and broader access. Verdiva acquired global development and commercialization rights (outside greater China and South Korea) to its portfolio from Sciwind Biosciences in 2024. The leadership team is led by CEO Khurem Farooq and Chairman Mark Pruzanski, and includes experienced drug‑development executives such as CMO Dr. Mohamed Eid. Verdiva launched with a substantial Series A financing to advance clinical programs and expand its cardiometabolic pipeline.

Total raised

$411M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2025